# Iloprost in Preventing Lung Cancer in Former Smokers

> **NCT02237183** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 34 (actual)

## Conditions studied

- Lung Carcinoma

## Interventions

- **DRUG:** Iloprost
- **OTHER:** Placebo Administration
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT02237183
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-05
- **Primary completion:** 2020-03-05
- **Final completion:** 2023-08-30
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2023-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02237183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02237183, "Iloprost in Preventing Lung Cancer in Former Smokers". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02237183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*